

# Jun Zhang

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/1382752/jun-zhang-publications-by-citations.pdf>

**Version:** 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

88

papers

58,936

citations

24

h-index

117

g-index

117

ext. papers

64,883

ext. citations

6.7

avg, IF

6.87

L-index

#	Paper	IF	Citations
88	Gapped BLAST and PSI-BLAST: a new generation of protein database search programs. <i>Nucleic Acids Research</i> , <b>1997</b> , 25, 3389-402	20.1	53786
87	Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients. <i>Science</i> , <b>2018</b> , 359, 97-103	33.3	1895
86	Exome sequencing of head and neck squamous cell carcinoma reveals inactivating mutations in NOTCH1. <i>Science</i> , <b>2011</b> , 333, 1154-7	33.3	1331
85	O and HO-Mediated Disruption of Fe Metabolism Causes the Differential Susceptibility of NSCLC and GBM Cancer Cells to Pharmacological Ascorbate. <i>Cancer Cell</i> , <b>2017</b> , 31, 487-500.e8	24.3	193
84	LKB1 inhibits lung cancer progression through lysyl oxidase and extracellular matrix remodeling. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2010</b> , 107, 18892-7	11.5	125
83	Low-Dose Apatinib Optimizes Tumor Microenvironment and Potentiates Antitumor Effect of PD-1/PD-L1 Blockade in Lung Cancer. <i>Cancer Immunology Research</i> , <b>2019</b> , 7, 630-643	12.5	93
82	High Discrepancy of Driver Mutations in Patients with NSCLC and Synchronous Multiple Lung Ground-Glass Nodules. <i>Journal of Thoracic Oncology</i> , <b>2015</b> , 10, 778-783	8.9	92
81	EGFR TKIs plus WBRT Demonstrated No Survival Benefit Other Than That of TKIs Alone in Patients with NSCLC and EGFR Mutation and Brain Metastases. <i>Journal of Thoracic Oncology</i> , <b>2016</b> , 11, 1718-28	8.9	92
80	HER2 exon 20 insertions in non-small-cell lung cancer are sensitive to the irreversible pan-HER receptor tyrosine kinase inhibitor pyrotinib. <i>Annals of Oncology</i> , <b>2019</b> , 30, 447-455	10.3	91
79	HER2, MET and FGFR2 oncogenic driver alterations define distinct molecular segments for targeted therapies in gastric carcinoma. <i>British Journal of Cancer</i> , <b>2014</b> , 110, 1169-78	8.7	77
78	Cystatin m: a novel candidate tumor suppressor gene for breast cancer. <i>Cancer Research</i> , <b>2004</b> , 64, 6957-64	6.1	74
77	Cystatin M suppresses the malignant phenotype of human MDA-MB-435S cells. <i>Oncogene</i> , <b>2004</b> , 23, 2206-15	6.15	69
76	Ethanol alters cellular activation and CD14 partitioning in lipid rafts. <i>Biochemical and Biophysical Research Communications</i> , <b>2005</b> , 332, 37-42	3.4	68
75	Hypoxia Induces Drug Resistance in Colorectal Cancer through the HIF-1 $\alpha$ /miR-338-5p/IL-6 Feedback Loop. <i>Molecular Therapy</i> , <b>2019</b> , 27, 1810-1824	11.7	55
74	Targeting DNA Replication Stress for Cancer Therapy. <i>Genes</i> , <b>2016</b> , 7,	4.2	47
73	Advanced stage melanoma therapies: Detailing the present and exploring the future. <i>Critical Reviews in Oncology/Hematology</i> , <b>2019</b> , 133, 99-111	7	40
72	Efficacy and Biomarker Analysis of Camrelizumab in Combination with Apatinib in Patients with Advanced Nonsquamous NSCLC Previously Treated with Chemotherapy. <i>Clinical Cancer Research</i> , <b>2021</b> , 27, 1296-1304	12.9	32

71	Early detection of lung cancer by using an autoantibody panel in Chinese population. <i>Oncolmmunology</i> , <b>2018</b> , 7, e1384108	7.2	31
70	Heterogeneity of PD-L1 Expression Among the Different Histological Components and Metastatic Lymph Nodes in Patients With Resected Lung Adenosquamous Carcinoma. <i>Clinical Lung Cancer</i> , <b>2018</b> , 19, e421-e430	4.9	28
69	EML4-ALK Fusion Detected by RT-PCR Confers Similar Response to Crizotinib as Detected by FISH in Patients with Advanced Non-Small-Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , <b>2015</b> , 10, 1546-52	8.9	28
68	Identification of recurrent fusion genes across multiple cancer types. <i>Scientific Reports</i> , <b>2019</b> , 9, 1074	4.9	24
67	Soil physical characteristics of a degraded tropical grassland and a reforestation implications for runoff generation. <i>Geoderma</i> , <b>2019</b> , 333, 163-177	6.7	24
66	LKB1 Tumor Suppressor: Therapeutic Opportunities Knock when LKB1 Is Inactivated. <i>Genes and Diseases</i> , <b>2014</b> , 1, 64-74	6.6	24
65	SBRT to adrenal metastases provides high local control with minimal toxicity. <i>Advances in Radiation Oncology</i> , <b>2017</b> , 2, 581-587	3.3	23
64	Small Molecule KRAS Agonist for Mutant KRAS Cancer Therapy. <i>Molecular Cancer</i> , <b>2019</b> , 18, 85	42.1	22
63	FANCD2 and DNA Damage. <i>International Journal of Molecular Sciences</i> , <b>2017</b> , 18,	6.3	22
62	The candidate tumor suppressor CST6 alters the gene expression profile of human breast carcinoma cells: down-regulation of the potent mitogenic, motogenic, and angiogenic factor autotaxin. <i>Biochemical and Biophysical Research Communications</i> , <b>2006</b> , 340, 175-82	3.4	22
61	Mutational Landscape of cfDNA Identifies Distinct Molecular Features Associated With Therapeutic Response to First-Line Platinum-Based Doublet Chemotherapy in Patients with Advanced NSCLC. <i>Theranostics</i> , <b>2017</b> , 7, 4753-4762	12.1	21
60	Mutated Fanconi anemia pathway in non-Fanconi anemia cancers. <i>Oncotarget</i> , <b>2015</b> , 6, 20396-403	3.3	20
59	Characterization of Liver Metastasis and Its Effect on Targeted Therapy in EGFR-mutant NSCLC: A Multicenter Study. <i>Clinical Lung Cancer</i> , <b>2017</b> , 18, 631-639.e2	4.9	19
58	Bisphosphonates enhance antitumor effect of EGFR-TKIs in patients with advanced EGFR mutant NSCLC and bone metastases. <i>Scientific Reports</i> , <b>2017</b> , 7, 42979	4.9	18
57	Metadherin enhances vulnerability of cancer cells to ferroptosis. <i>Cell Death and Disease</i> , <b>2019</b> , 10, 682	9.8	18
56	Modulation of Bax and mTOR for Cancer Therapeutics. <i>Cancer Research</i> , <b>2017</b> , 77, 3001-3012	10.1	17
55	Novel antibodies against GPIIb/IIIa inhibit pulmonary metastasis by affecting vWF-GPIIb/IIIa interaction. <i>Journal of Hematology and Oncology</i> , <b>2018</b> , 11, 117	22.4	17
54	Targeting HER (ERBB) signaling in head and neck cancer: An essential update. <i>Molecular Aspects of Medicine</i> , <b>2015</b> , 45, 74-86	16.7	16

53	Honokiol Radiosensitizes Squamous Cell Carcinoma of the Head and Neck by Downregulation of Survivin. <i>Clinical Cancer Research</i> , <b>2018</b> , 24, 858-869	12.9	16
52	Addition of bevacizumab for malignant pleural effusion as the manifestation of acquired EGFR-TKI resistance in NSCLC patients. <i>Oncotarget</i> , <b>2017</b> , 8, 62648-62657	3.3	15
51	Prognostic significance of Daxx NCR (Nuclear/Cytoplasmic Ratio) in gastric cancer. <i>Cancer Medicine</i> , <b>2017</b> , 6, 2063-2075	4.8	14
50	OA04.03 A Randomized Phase 3 Study of Camrelizumab plus Chemotherapy as 1st Line Therapy for Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , <b>2019</b> , 14, S215-S216	8.9	14
49	Runoff response and sediment yield of a landslide-affected fire-climax grassland micro-catchment (Leyte, the Philippines) before and after passage of typhoon Haiyan. <i>Journal of Hydrology</i> , <b>2018</b> , 565, 524-537	6	13
48	Defined genetic events associated with the spontaneous in vitro transformation of ELA/Ras-expressing human IMR90 fibroblasts. <i>Carcinogenesis</i> , <b>2006</b> , 27, 350-9	4.6	13
47	Large Scale, Multicenter, Prospective Study of Apatinib in Advanced Gastric Cancer: A Real-World Study from China. <i>Cancer Management and Research</i> , <b>2020</b> , 12, 6977-6985	3.6	13
46	Feasibility of cytological specimens for ALK fusion detection in patients with advanced NSCLC using the method of RT-PCR. <i>Lung Cancer</i> , <b>2016</b> , 94, 28-34	5.9	12
45	Harnessing DNA Replication Stress for Novel Cancer Therapy. <i>Genes</i> , <b>2020</b> , 11,	4.2	12
44	Relating Gut Microbiome and Its Modulating Factors to Immunotherapy in Solid Tumors: A Systematic Review. <i>Frontiers in Oncology</i> , <b>2021</b> , 11, 642110	5.3	12
43	Photodynamic therapy synergizes with PD-L1 checkpoint blockade for immunotherapy of CRC by multifunctional nanoparticles. <i>Molecular Therapy</i> , <b>2021</b> , 29, 2931-2948	11.7	10
42	Prospective correlation between the patient microbiome with response to and development of immune-mediated adverse effects to immunotherapy in lung cancer. <i>BMC Cancer</i> , <b>2021</b> , 21, 808	4.8	10
41	Immunotherapy with Dendritic Cells Modified with Tumor-Associated Antigen Gene Demonstrates Enhanced Antitumor Effect Against Lung Cancer. <i>Translational Oncology</i> , <b>2017</b> , 10, 132-141	4.9	9
40	Targeting KRAS-mutant non-small cell lung cancer: challenges and opportunities. <i>Acta Biochimica Et Biophysica Sinica</i> , <b>2016</b> , 48, 11-6	2.8	9
39	Effectiveness and safety of low-dose apatinib in advanced gastric cancer: A real-world study. <i>Cancer Medicine</i> , <b>2020</b> , 9, 5008-5014	4.8	9
38	MTDH/AEG-1 downregulation using pristimerin-loaded nanoparticles inhibits Fanconi anemia proteins and increases sensitivity to platinum-based chemotherapy. <i>Gynecologic Oncology</i> , <b>2019</b> , 155, 349-358	4.9	8
37	Endobronchial aspergilloma: A case report and literature review. <i>Experimental and Therapeutic Medicine</i> , <b>2017</b> , 14, 547-554	2.1	8
36	Understanding Microbiome Effect on Immune Checkpoint Inhibition in Lung Cancer: Placing the Puzzle Pieces Together. <i>Journal of Immunotherapy</i> , <b>2018</b> , 41, 359-360	5	8

35	Atezolizumab after Nivolumab-Induced Inflammatory Polyarthritis: Can Anti-PD-L1 Immunotherapy Be Administered after Anti-PD-1-Related Immune Toxicities?. <i>Journal of Thoracic Oncology</i> , <b>2018</b> , 13, e102-e103	8.9	8
34	Phenformin enhances the therapeutic effect of selumetinib in KRAS-mutant non-small cell lung cancer irrespective of LKB1 status. <i>Oncotarget</i> , <b>2017</b> , 8, 59008-59022	3.3	7
33	Bugs in the system: bringing the human microbiome to bear in cancer immunotherapy. <i>Gut Microbes</i> , <b>2019</b> , 10, 109-112	8.8	6
32	Mutational Landscape and Evolutionary Pattern of Liver and Brain Metastasis in Lung Adenocarcinoma. <i>Journal of Thoracic Oncology</i> , <b>2021</b> , 16, 237-249	8.9	6
31	Lobar versus sub-lobar surgery for pulmonary typical carcinoid, a population-based analysis. <i>Journal of Thoracic Disease</i> , <b>2018</b> , 10, 5850-5859	2.6	6
30	Novel expression of CST1 as candidate senescence marker. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , <b>2011</b> , 66, 723-31	6.4	5
29	Ophiopogon japonicus inhibits radiation-induced pulmonary inflammation in mice. <i>Annals of Translational Medicine</i> , <b>2019</b> , 7, 622	3.2	5
28	Water budget and run-off response of a tropical multispecies forest and effects of typhoon disturbance. <i>Ecohydrology</i> , <b>2019</b> , 12, e2055	2.5	5
27	ROR1 Potentiates FGFR Signaling in Basal-Like Breast Cancer. <i>Cancers</i> , <b>2019</b> , 11,	6.6	4
26	Cell Block as a Surrogate for Programmed Death-Ligand 1 Staining Testing in Patients of Non-Small Cell Lung Cancer. <i>Journal of Cancer</i> , <b>2020</b> , 11, 551-558	4.5	4
25	Targeting interleukin-1 and inflammation in lung cancer.. <i>Biomarker Research</i> , <b>2022</b> , 10, 5	8	4
24	The Serum Level of IL-1B Correlates with the Activity of Chronic Pulmonary Aspergillosis. <i>Canadian Respiratory Journal</i> , <b>2018</b> , 2018, 8740491	2.1	4
23	Central Nervous System Pseudoprogression With Nivolumab in a Patient With Squamous Cell Lung Cancer Followed by Prolonged Response. <i>Journal of Thoracic Oncology</i> , <b>2018</b> , 13, e183-e184	8.9	4
22	Tuberculosis in umbilical cord blood transplant recipients: clinical characteristics and challenges. <i>Bone Marrow Transplantation</i> , <b>2015</b> , 50, 465-8	4.4	3
21	IMpower, CASPIAN, and more: exploring the optimal first-line immunotherapy for extensive-stage small cell lung cancer. <i>Journal of Hematology and Oncology</i> , <b>2020</b> , 13, 69	22.4	3
20	Pten-NOLC1 fusion promotes cancers involving MET and EGFR signalings. <i>Oncogene</i> , <b>2021</b> , 40, 1064-1076	9.2	3
19	Characterization of evolution trajectory and immune profiling of brain metastasis in lung adenocarcinoma. <i>Npj Precision Oncology</i> , <b>2021</b> , 5, 6	9.8	3
18	Consensus for HER2 alterations testing in non-small-cell lung cancer.. <i>ESMO Open</i> , <b>2022</b> , 7, 100395	6	2

17	Impact of ALK variants on brain metastasis and treatment response in advanced NSCLC patients with oncogenic ALK fusion. <i>Translational Lung Cancer Research</i> , <b>2020</b> , 9, 1452-1463	4.4	2
16	Prospective longitudinal study of kinetics of humoral response to one, two, or three doses of SARS-CoV-2 vaccine in hematopoietic cell transplant recipients.. <i>Bone Marrow Transplantation</i> , <b>2022</b> , 10, 100-107	4.4	2
15	Targeting KRAS mutant non-small cell lung cancer (NSCLC) with deltarasin: A small molecule inhibitor of KRAS-PDE4 interaction.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, e13597-e13597	2.2	1
14	Prospective correlation between the patient microbiome with response to and development of immune-mediated adverse effects to immunotherapy in lung cancer.. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, e21024-e21024	2.2	1
13	DRAGoM: Classification and Quantification of Noncoding RNA in Metagenomic Data. <i>Frontiers in Genetics</i> , <b>2021</b> , 12, 669495	4.5	1
12	DCLK1 isoforms and aberrant Notch signaling in the regulation of human and murine colitis. <i>Cell Death Discovery</i> , <b>2021</b> , 7, 169	6.9	1
11	Tying Small Changes to Large Outcomes: The Cautious Promise in Incorporating the Microbiome into Immunotherapy. <i>International Journal of Molecular Sciences</i> , <b>2021</b> , 22, 10000	6.3	1
10	Mutational landscape of circulating tumor DNA identifies distinct molecular features associated with therapeutic response in patients with metastatic colorectal cancer.. <i>Therapeutic Advances in Medical Oncology</i> , <b>2022</b> , 14, 17588359211070643	5.4	0
9	NEK2 as a prognostic marker and therapeutic target in adenocarcinoma of the lung.. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, e23282-e23282	2.2	0
8	Response to Erlotinib in a Patient with Compound EGFR L747S and Exon 19 Deletion. <i>Journal of Thoracic Oncology</i> , <b>2018</b> , 13, e129-e130	8.9	0
7	Pharmacological ascorbate improves the response to platinum-based chemotherapy in advanced stage non-small cell lung cancer.. <i>Redox Biology</i> , <b>2022</b> , 53, 102318	11.3	0
6	Lung cancer liquid biopsy assays by qPCR using iDDS probe and Wild Terminator methods.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, e21178-e21178	2.2	0
5	Novel Antibodies Against Glycoprotein Ib Inhibit Pulmonary Metastasis By Affecting Vwf-GpIb Interaction. <i>Blood</i> , <b>2018</b> , 132, 1133-1133	2.2	0
4	Phenformin combines with selumetinib in targeting KRAS mutant non-small cell lung cancer cells with alternative LKB1 status.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 2589-2589	2.2	0
3	Surgical management of pulmonary typical carcinoids: A population-based analysis.. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 8540-8540	2.2	0
2	Retrospective comparison between high-dose cisplatin and less-intensive weekly cisplatin/paclitaxel concurrently with radiation for locally advanced head and neck cancer (LAHNC).. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, e17535-e17535	2.2	0
1	Combination of atezolizumab and pirfenidone in second-line and beyond NSCLC: A phase I/II study.. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, TPS2678-TPS2678	2.2	0